O1385

Ozagrel hydrochloride hydrate

≥98% (HPLC), solid

• Sinónimos: (E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
• Fórmula empírica (notación de Hill): C₁₃H₁₂N₂O₂ · HCl · xH₂O
• Número CAS: 78712-43-3
• Peso molecular: 264.71 (anhydrous basis)
• NACRES: NA.77
• PubChem Substance ID: 24897942
• UNSPSC Code: 12352200
• MDL number: MFCD00911569
• Assay: ≥98% (HPLC)
• Form: solid
• Storage condition: desiccated

Propiedades

• assay: ≥98% (HPLC)
• form: solid
• storage condition: desiccated
• color: white to off-white
• solubility: H₂O: soluble
• storage temp.: room temp
• SMILES string: O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
• InChI: 1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
• InChI key: OWIZTYOMGVTSDP-TXOOBNKBSA-N

Descripción

Application

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:

• in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction[1]
• to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes[2]
• to test its effect on arteriolar vasoconstriction in hyperglycemic mice[3]

Biochem/physiol Actions

Ozagrel is a selective thromboxane A₂ synthase (TXA₂) inhibitor.

Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation.[4] Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia.[4] It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).[5]

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)